ResearcherHarvard UniversityNo recent work listed

Miguel Ángel Hernán

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1619-8456; OpenAlex author ID A5084268825. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper

Papers 1

Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data. Last author DOI 10.1016/j.annepidem.2022.12.005 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Devon J. Boyne · 1 shared paper, 2023 · strength 0.19
- Paper Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target tr… DOI 10.1016/j.annepidem.2022.12.005 ↗
Darren R. Brenner · 1 shared paper, 2023 · strength 0.19
- Paper Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target tr… DOI 10.1016/j.annepidem.2022.12.005 ↗
Winson Y. Cheung · 1 shared paper, 2023 · strength 0.19
- Paper Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target tr… DOI 10.1016/j.annepidem.2022.12.005 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.